[The role of vinpocetine in the treatment of cerebrovascular diseases based in human studies].
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing published human clinical studies and neuroimaging findings without reported systematic review methodology
PubMed 17631470 · doi:10.1556/OH.2007.28115
What was done
This review summarized clinical and neuroimaging evidence evaluating the effects and indications of vinpocetine in patients with acute and chronic cerebrovascular diseases. The authors synthesized findings from positron emission tomography (PET), transcranial Doppler (TCD), single-photon emission computed tomography (SPECT), near-infrared spectroscopy (NIRS), hemorheological assessments, and international clinical trial meta-analyses.
What was found
The abstract reports no numerical values, effect sizes, or statistical confidence intervals. The authors reported that evidence is lacking for vinpocetine in acute ischemic stroke, with only a few small studies showing slight improvement. For chronic cerebrovascular disease, cited literature indicated increased cerebral perfusion, elevated oxygen and glucose consumption, improved rheologic parameters, and significant improvements in cognitive achievement and quality of life.
Why it matters
This review summarizes the clinical landscape for vinpocetine, indicating potential metabolic, hemodynamic, and cognitive utility in chronic cerebral hypoperfusion while noting that data remain insufficient to support its use in acute stroke.
Limits
The abstract provides no sample sizes, specific trial designs, search strategy details, or quantitative data. Adverse events and safety outcomes were not described.
Cited by
- supports Brain SPECT imaging studies demonstrate that Ginkgo biloba and vinpocetine increase cerebral blood flow.